In a 76‑year‑old man taking levetiracetam (Keppra) 500 mg twice daily with a serum concentration of 5.7 µg/mL, is this level therapeutic and what dose adjustment is recommended?

Levetiracetam Level Interpretation and Dose Adjustment

Current Level Assessment

The serum levetiracetam concentration of 5.7 µg/mL is subtherapeutic, falling well below the established therapeutic range of 12–46 µg/mL, and the current dose of 500 mg twice daily is inadequate for this 76-year-old patient. 1

Recommended Dose Adjustment

Increase levetiracetam to 1000 mg twice daily (500 mg BID → 1000 mg BID), which represents a standard maintenance dose for adults and should achieve therapeutic concentrations. 2, 3

Rationale for Dose Escalation

• The current dose of 500 mg twice daily (1000 mg total daily) is at the lower end of the therapeutic spectrum and clearly insufficient based on the measured level 2
• Standard maintenance dosing for adults ranges from 1000–1500 mg twice daily, with 1000 mg BID being a well-established and safe target 4, 5
• The patient's age (76 years) does not contraindicate standard dosing, though renal function must be verified before escalation 6, 5

Critical Renal Function Assessment

Before increasing the dose, obtain serum creatinine and calculate creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR), as levetiracetam clearance is directly dependent on renal function—66% of the drug is eliminated unchanged in urine. 6, 5

Renal-Adjusted Dosing Algorithm

If renal function testing reveals impairment, adjust according to the following schedule 2:

• CrCl >80 mL/min (Normal): 500–1500 mg every 12 hours
• CrCl 50–80 mL/min (Mild): 500–1000 mg every 12 hours
• CrCl 30–50 mL/min (Moderate): 250–750 mg every 12 hours
• CrCl <30 mL/min (Severe): 250–500 mg every 12 hours
• ESRD on dialysis: 500–1000 mg every 24 hours (with supplemental dose after dialysis)

Practical Implementation

• If eGFR is normal (>80 mL/min), proceed directly to 1000 mg twice daily 5
• If eGFR is 50–80 mL/min, the current 500 mg BID may already be appropriate, but the subtherapeutic level suggests either non-compliance or the need for 750–1000 mg BID 5
• In elderly patients, total body clearance decreases with declining renal function, making dose adjustment essential to prevent both under- and over-dosing 7, 5

Monitoring Strategy

Recheck serum levetiracetam concentration 3–5 days after dose adjustment to confirm achievement of therapeutic levels (target 12–46 µg/mL), as steady-state is reached within 2 days due to the drug's short half-life of approximately 7 hours in patients with normal renal function. 7, 6

Additional Monitoring Parameters

• Assess for compliance issues before attributing low levels solely to inadequate dosing—non-compliance is a common cause of subtherapeutic concentrations 1
• Monitor complete blood count periodically, though routine therapeutic drug monitoring is not required once stable dosing is established 2
• Watch for adverse effects including somnolence, dizziness, mood changes, and rarely rhabdomyolysis (monitor CK if muscle symptoms develop) 8

Common Pitfalls to Avoid

• Do not assume the low level is due to non-compliance without first verifying renal function—elderly patients often have reduced creatinine clearance that may not be reflected in serum creatinine alone due to decreased muscle mass 5
• Do not underdose in elderly patients out of excessive caution—levetiracetam has a wide therapeutic window and minimal drug interactions, making it particularly suitable for older adults 6
• Do not delay dose adjustment while waiting for repeat levels—the current concentration is clearly subtherapeutic and requires immediate action 1
• Avoid using serum creatinine alone to assess renal function in the elderly—calculate CrCl using Cockcroft-Gault or eGFR using CKD-EPI equations, as serum creatinine underestimates renal impairment in older patients with reduced muscle mass 5

Special Considerations in This Patient

• At 76 years old, this patient likely has some degree of age-related decline in renal function even if serum creatinine appears normal 5
• Levetiracetam's favorable pharmacokinetic profile—minimal protein binding, lack of hepatic metabolism, and absence of cytochrome P450 interactions—makes it an excellent choice for elderly patients on multiple medications 6
• The half-life may be prolonged to 10–18 hours in patients with renal impairment, requiring less frequent dosing adjustments 7, 4